行情

CYCC

CYCC

Cyclacel Pharms
NASDAQ

实时行情|Nasdaq Last Sale

0.3680
+0.0014
+0.38%
交易中 12:35 10/22 EDT
开盘
0.3680
昨收
0.3666
最高
0.3681
最低
0.3677
成交量
2,634
成交额
--
52周最高
1.420
52周最低
0.2813
市值
632.96万
市盈率(TTM)
-0.6250
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CYCC 新闻

  • 午盘:财报好坏参半 美股维持窄幅震荡
  • 新浪美股.45分钟前
  • 美国财长姆努钦:已告诉FB目前发行Libra还不成熟
  • 新浪美股.1小时前
  • 因对阿根廷看走眼 富兰克林新兴市场基金被晨星降级
  • 新浪美股.1小时前
  • 美联储周二定期回购操作一个月来首次获得超额认购
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
+0.50%
制药与医学研究
+1.07%

热门股票

名称
价格
涨跌幅

CYCC 简况

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.
展开

Webull提供Cyclacel Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。